Laurel Wealth Advisors LLC Grows Holdings in IDEXX Laboratories, Inc. $IDXX

Laurel Wealth Advisors LLC boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 53,536.4% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 11,800 shares of the company’s stock after acquiring an additional 11,778 shares during the quarter. Laurel Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $6,329,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Mutual of America Capital Management LLC grew its position in shares of IDEXX Laboratories by 79.6% during the first quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock worth $8,160,000 after buying an additional 8,609 shares in the last quarter. Arkadios Wealth Advisors bought a new position in IDEXX Laboratories during the 2nd quarter valued at $405,000. Plato Investment Management Ltd grew its holdings in IDEXX Laboratories by 37.1% during the 1st quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock worth $1,310,000 after acquiring an additional 835 shares in the last quarter. Genesis Wealth Advisors LLC acquired a new position in IDEXX Laboratories during the 2nd quarter worth $215,000. Finally, ORG Wealth Partners LLC acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at about $273,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the sale, the executive vice president directly owned 21,149 shares in the company, valued at $14,874,937.66. This trade represents a 30.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.98% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of research reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of IDEXX Laboratories in a research note on Tuesday. Jefferies Financial Group reiterated a “buy” rating and issued a $830.00 target price on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Leerink Partners set a $785.00 price target on IDEXX Laboratories in a research report on Monday, November 3rd. Wall Street Zen upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 16th. Finally, BTIG Research lifted their price objective on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average target price of $730.50.

IDEXX Laboratories Trading Down 1.4%

Shares of NASDAQ IDXX opened at $755.96 on Thursday. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98. The company has a market cap of $60.36 billion, a price-to-earnings ratio of 62.94, a price-to-earnings-growth ratio of 4.06 and a beta of 1.62. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The stock’s 50 day simple moving average is $663.01 and its 200 day simple moving average is $602.29.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, November 3rd. The company reported $3.22 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. The firm had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm’s revenue was up 13.3% on a year-over-year basis. During the same period in the prior year, the business earned $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.